Clinical trials
Lung Diseases trials in Sweden
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Recruiting | 11 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 2 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 9 |
| Dalarna County Council, Sweden | 3 |
| United Therapeutics | 2 |
| AIRNA Corporation | 1 |
| Danderyd Hospital | 1 |
| Eli Lilly and Company | 1 |
| Grifols Therapeutics LLC | 1 |
| Hoffmann-La Roche | 1 |
| Karolinska Institutet | 1 |
| Lund University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Diseases | 31 |
| Respiratory Tract Diseases | 12 |
| Pulmonary Disease, Chronic Obstructive | 8 |
| Lung Diseases, Obstructive | 7 |
| Asthma | 6 |
| Bronchial Diseases | 6 |
| Cardiovascular Diseases | 6 |
| Pathologic Processes | 4 |
| Emphysema | 3 |
| Neoplasms | 3 |
Trials
Showing 76 to 31 of 31. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.